MLRT 10-Q
Metalert, Inc. (MLRT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark one)
For
the quarterly period ended
OR
For the transition period from __________ to __________
Commission
file number
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of | (I.R.S. Employer | |
| incorporation or organization) | Identification No.) |
| (Address of principal executive offices) (Zip Code) |
| ( |
| (Registrant’s telephone number, including area code) |
(Former name, former address and former fiscal year, if changed since last report.)
| Title of each class registered: | Trading Symbol(s) | Name of each exchange on which registered: | ||
| None |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |
| ☐ (Do not check if a smaller reporting company) | Smaller reporting company | |||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes
☐
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: common shares issued and outstanding as of August 12, 2022.
GTX CORP AND SUBSIDIARIES
For the quarter ended June 30, 2022
FORM 10-Q
| 2 |
PART I
ITEM 1. FINANCIAL STATEMENTS
GTX CORP AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, 2022 | December 31, 2021 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Accounts receivable, net | ||||||||
| Inventory | ||||||||
| Investment in marketable securities | ||||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Accrued expenses, related parties | ||||||||
| Deferred revenues | ||||||||
| Short-term debt – line of credit | ||||||||
| Short-term debt - Care loans | ||||||||
| Convertible promissory notes, past due | ||||||||
| Convertible notes, related parties, net of discount | ||||||||
| Notes payable | ||||||||
| Total current liabilities | ||||||||
| Long-term debt - CARE loan, net of current | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies | ||||||||
| Stockholders’ deficit: | ||||||||
| Preferred stock series A, $ par value; shares authorized; shares issued and outstanding at June 30, 2022 and December 31, 2021 | ||||||||
| Preferred stock series B, $ par value; shares authorized, and issued and outstanding at June 30, 2022 and December 31, 2021, respectively | ||||||||
| Preferred stock series C, $ par value; shares authorized, and issued and outstanding at June 30, 2022 and December 31, 2021, respectively | ||||||||
| Common stock, $ par value; shares authorized; and shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities and stockholders’ deficit | $ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
| 3 |
GTX CORP AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Product sales | $ | $ | $ | $ | ||||||||||||
| Service income | ||||||||||||||||
| Total revenues | ||||||||||||||||
| Cost of products sold | ||||||||||||||||
| Cost of other revenue | ||||||||||||||||
| Total cost of goods sold | ||||||||||||||||
| Gross margin | ||||||||||||||||
| Operating expenses: | ||||||||||||||||
| Wages and benefits | ||||||||||||||||
| Professional fees | ||||||||||||||||
| Sales and marketing expenses | ||||||||||||||||
| General and administrative | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Income/(loss) from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income/(expenses): | ||||||||||||||||
| Gain/(loss) on settlement of debt | ( | ) | ||||||||||||||
| Gain/(loss) on marketable securities | ( | ) | ( | ) | ( | ) | ||||||||||
| Amortization of debt discount | ( | ) | ( | ) | ||||||||||||
| Grant from Care loans | ||||||||||||||||
| Interest imputed on related party notes | ( | ) | ( | ) | ||||||||||||
| Interest expense and financing costs | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other income/(expenses) | ( | ) | ( | ) | ( | ) | ||||||||||
| Net income/(loss) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Deemed dividend to series-B preferred stockholders | ||||||||||||||||
| Deemed dividend to series-C preferred stockholders | ( | ) | ( | ) | ||||||||||||
| Net income/(loss) attributable to common shareholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of common shares outstanding - basic and diluted | ||||||||||||||||
| Net income/(loss) per common share - basic and diluted | $ | $ | $ | $ | ||||||||||||
See accompanying notes to condensed consolidated financial statements.
| 4 |
GTX CORP AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
Three Months Ended June 30, 2022 and June 30, 2021 (Unaudited)
For the Three Months Ended June 30, 2022 (Unaudited)
| Series A Preferred | Series B Preferred | Series C Preferred | Common Shares | Additional | ||||||||||||||||||||||||||||||||||||||||
| Shares | Shares | Shares | Shares | Paid-In | Accumulated | Equity | ||||||||||||||||||||||||||||||||||||||
| Issued | Amount | Issued | Amount | Issued | Amount | Issued | Amount | Capital | Deficit | (Deficit) | ||||||||||||||||||||||||||||||||||
| Balance March 31, 2022 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| financings | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Balance June 30, 2022 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
For the Three Months Ended June 30, 2021 (Unaudited)
| Series A Preferred | Series B Preferred | Series C Preferred | Common Shares | Additional | ||||||||||||||||||||||||||||||||||||||||
| Shares | Shares | Shares | Shares | Paid-In | Accumulated | Equity | ||||||||||||||||||||||||||||||||||||||
| Issued | Amount | Issued | Amount | Issued | Amount | Issued | Amount | Capital | Deficit | (Deficit) | ||||||||||||||||||||||||||||||||||
| Balance March 31, 2021 | $ | $ | $ | $ | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Loss on stock compensation | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for conversion of debt | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Issuance of preferred stock for financings | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for the conversion of preferred shares | - | ( |
) | - | ( |
) | ||||||||||||||||||||||||||||||||||||||
| Deemed dividend on fair value of warrants & conversion feature | - | - | - | - | ( |
) | ||||||||||||||||||||||||||||||||||||||
| Imputed interest – related parties | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | - | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||
| Balance June 30, 2021 | $ | $ | $ | $ | $ | $ | ( |
) | $ | ( |
) | |||||||||||||||||||||||||||||||||
| 5 |
GTX CORP AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
Six Months Ended June 30, 2022 and June 30, 2021 (Unaudited)
For the Six Months Ended June 30, 2022 (Unaudited)
| Series A Preferred | Series B Preferred | Series C Preferred | Common Shares | Additional | ||||||||||||||||||||||||||||||||||||||||
| Shares | Shares | Shares | Shares | Paid-In | Accumulated | Equity | ||||||||||||||||||||||||||||||||||||||
| Issued | Amount | Issued | Amount | Issued | Amount | Issued | Amount | Capital | Deficit | (Deficit) | ||||||||||||||||||||||||||||||||||
| Balance December 31, 2021 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for financings | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for the conversion of warrants | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Balance June 30, 2022 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
For the Six Months Ended June 30, 2021 (Unaudited)
| Series A Preferred | Series B Preferred | Series C Preferred | Common Shares | Additional | ||||||||||||||||||||||||||||||||||||||||
| Shares | Shares | Shares | Shares | Paid-In | Accumulated | Equity | ||||||||||||||||||||||||||||||||||||||
| Issued | Amount | Issued | Amount | Issued | Amount | Issued | Amount | Capital | Deficit | (Deficit) | ||||||||||||||||||||||||||||||||||
| Balance December 31, 2020 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Loss on stock compensation | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for conversion of debt | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Issuance of preferred stock for financings | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for financings | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for the conversion of warrants | - | - | - | ( | ) | |||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for the conversion of preferred shares | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||
| Loss on shares issued for conversion of debt | ||||||||||||||||||||||||||||||||||||||||||||
| Deemed dividend on fair value of warrants & conversion feature | - | - | - | - | ( | ) | ||||||||||||||||||||||||||||||||||||||
| Imputed interest – related parties | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Inpixon loan reduction correction | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Net income (loss) | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Balance June 30, 2021 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
See accompanying notes to condensed consolidated financial statements.
| 6 |
GTX CORP AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| Six Months Ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Cash flows from operating activities | ||||||||
| Net income / (loss) | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net income / (loss) to net cash used in operating activities: | ||||||||
| Depreciation and amortization | ||||||||
| Change in fair value of marketable securities | ( | ) | ||||||
| Stock based compensation | ||||||||
| Grant from CARE loans | ( | ) | ||||||
| Amortization of debt discount | ||||||||
| Issuance of common stock for financings | ||||||||
| Loss on the settlement of debt and accrued interest | ||||||||
| Fair value of warrants issued for services | ||||||||
| Imputed interest on related party notes | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ||||||
| Inventory | ||||||||
| Other current and non-current assets | ( | ) | ||||||
| Accounts payable and accrued expenses | ||||||||
| Accrued expenses - related parties | ||||||||
| Deferred revenues | ( | ) | ( | ) | ||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities | ||||||||
| PP&E purchases | ( | ) | ||||||
| Proceeds from the sale of marketable securities | ||||||||
| Net cash used in investing activities | ( | ) | ||||||
| Cash flows from financing activities | ||||||||
| Proceeds from line of credit | ||||||||
| Proceeds from issuance of preferred stock | ||||||||
| Proceeds from the exercise of warrants | ||||||||
| Proceeds from Reg A | ||||||||
| Borrowings on debt | ||||||||
| Payments on notes | ( | ) | ||||||
| Payments on line of credit | ( | ) | ||||||
| Payments on debt | ( | ) | ( | ) | ||||
| Net cash provided by financing activities | ||||||||
| Net change in cash and cash equivalents | ( | ) | ||||||
| Cash and cash equivalents, beginning of period | ||||||||
| Cash and cash equivalents, end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Income taxes paid | $ | $ | ||||||
| Interest paid | $ | $ | ||||||
| Supplemental disclosure of noncash investing and financing activities: | ||||||||
| Issuance of common stock for conversion of debt and interest | $ | $ | ||||||
| Deemed dividend | $ | $ | ||||||
| Conversion of preferred stock to common stock | $ | $ | ||||||
See accompanying notes to condensed consolidated financial statements.
| 7 |
GTX CORP AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND 2021
(Unaudited)
1. ORGANIZATION AND BASIS OF PRESENTATION
During
the periods covered by these financial statements, GTX Corp and its subsidiaries (the “Company”, “GTX”, “we”,
“us”, and “our”) were engaged in business operations that design, manufacture and sell various interrelated and
complementary products and services in the wearable technology and Personal Location Services marketplace. GTX owns
Global Trek Xploration, Inc. focuses on the design, manufacturing and sales distribution of its hardware, software, and connectivity, Global Positioning System (“GPS”) and Bluetooth Low Energy (“BLE”) monitoring and tracking platform, which provides real-time tracking and monitoring of people and high valued assets. Utilizing a miniature quad-band GPRS transceiver, antenna, circuitry, battery and inductive charging pad our solutions can be customized and integrated into numerous products whose location and movement can be monitored in real time over the Internet through our 24x7 tracking portal or on a web enabled cellular telephone. Our core products and services are supported by an intellectual property (“IP”) portfolio of patents, patents pending, registered trademarks, copyrights, URLs and a library of software source code, all of which is also managed by Global Trek.
LOCiMOBILE, Inc., is the Companies digital platform which has been at the forefront of Smartphone application (“App”) development since 2008. With a suite of mobile applications that turn the iPhone, iPad, Android and other GPS enabled handsets into a tracking device which can be tracked from handset to handset or through our tracking portal or on any connected device with internet access. LOCiMOBILE has launched over 20 Apps across multi mobile device operating systems and continues to launch consumer and enterprise apps.
Basis of Presentation
The accompanying unaudited consolidated financial statements of GTX have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and applicable regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been omitted pursuant to such rules and regulations. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of financial position and results of operations have been included. Our operating results for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The accompanying unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2021, which are included in our Annual Report on Form 10-K.
The accompanying consolidated financial statements reflect the accounts of GTX Corp and its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated.
Going Concern
The
consolidated financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets
and discharge its liabilities in the normal course of business for the foreseeable future. The Company has a stockholders’ deficit
of $
| 8 |
The Company’s independent registered public accounting firm has also included explanatory language in their opinion accompanying the Company’s audited financial statements for the year ended December 31, 2021. The Company’s financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.
The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. The Company’s ability to raise additional capital through the future issuances of debt or equity is unknown. The ability to obtain additional financing, the successful development of the Company’s contemplated plan of operations, or its ability to achieve profitable operations are necessary for the Company to continue operations, and there is no assurance that these can be achieved. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.
2. SIGNIFICANT ACCOUNTING POLICIES
Revenue Recognition
The Company recognizes revenue in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which include (1) identifying the contract or agreement with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied.
The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Revenue and costs of sales are recognized when control of the products transfers to our customer, which generally occurs upon shipment from our facilities. The Company’s performance obligations are satisfied at that time.
All of the Company’s products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them.
The Company does not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.
We derive our revenues primarily from hardware sales, subscription services fees, IP licensing and professional services fees. Hardware includes our SmartSole, Military and other Stand-Alone Devices. Subscription services revenues consist of fees from customers accessing our cloud-based software solutions and subscription or license fees for our platform. Professional services and other revenues consist primarily of fees from implementation services, configuration, data services, training and managed services related to our solutions. IP licensing is related to our agreement with Inventergy whereby we have partnered in order to monetize our IP portfolio.
Product sales
At the inception of each contract, we assess the goods and services promised in our contracts and identify each distinct performance obligation. The Company recognizes revenue upon the transfer of control of promised products or services to the customer in an amount that depicts the consideration the Company expects to be entitled to for the related products or services. For the large majority of the Company’s sales, transfer of control occurs once product has shipped and title and risk of loss have transferred to the customer.
| 9 |
Services Income
The Company’s software solutions are available for use as hosted application arrangements under subscription fee agreements without licensing perpetual rights to the software. Subscription fees from these applications are recognized over time on a ratable basis over the customer agreement term beginning on the date the Company’s solution is made available to the customer. Our subscription contracts are generally one to three months in length. Amounts that have been invoiced are recorded in accounts receivable and deferred revenues or revenues, depending on whether the revenue recognition criteria have been met.
The majority of our professional services arrangements are recognized on a time and materials basis. Professional services revenues recognized on a time and materials basis are measured monthly based on time incurred and contractually agreed upon rates. Certain professional services revenues are based on fixed fee arrangements and revenues are recognized based on the proportional performance method. In some cases, the terms of our time and materials and fixed fee arrangements may require that we defer the recognition of revenue until contractual conditions are met. Data services and training revenues are generally recognized as the services are performed.
IP Licensing Revenue
Licensing revenue recorded by the Company relates exclusively to the Company’s License and Partnership agreement with Inventergy which provides for ongoing royalties based on monetization of IP licenses. The Company recognizes revenue for royalties under ASC 606, which provides revenue recognition constraints by requiring the recognition of revenue at the later of the following: 1) sale or usage of the products or 2) satisfaction of the performance obligations. The Company has satisfied its performance obligations and therefore recognizes licensing revenue when the sales to which the license(s) relate are completed. During the periods ended June 30, 2022 and June 30, 2021, the Company did not recognize any licensing revenue.
Disaggregation of Net Sales
The following table shows the Company’s disaggregated net sales by product type:
| June 30, 2022 | June 30, 2021 | |||||||
| Product sales | $ | $ | ||||||
| Service income | ||||||||
| IP and consulting income | ||||||||
| Total | $ | $ | ||||||
The following table shows the Company’s disaggregated net sales by customer type:
| June 30, 2022 | June 30, 2021 | |||||||
| B2B | $ | $ | ||||||
| B2C | ||||||||
| Military | ||||||||
| IP | ||||||||
| Total | $ | $ | ||||||
Allowance for Doubtful Accounts
We
extend credit based on our evaluation of the customer’s financial condition. We carry our accounts receivable at net
realizable value. We monitor our exposure to losses on receivables and maintain allowances for potential losses or adjustments. We
determine these allowances by (1) evaluating the aging of our receivables; and (2) reviewing high-risk customers financial
condition. Past due receivable balances are written off when our internal collection efforts have been unsuccessful in collecting
the amount due. Our allowance for doubtful accounts was $
| 10 |
Shipping and Handling Costs
Shipping and handling costs are included in cost of goods sold in the accompanying consolidated statements of operations.
Product Warranty
Use of Estimates
The preparation of the accompanying unaudited financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, estimates related to revenue recognition, allowance for doubtful accounts, inventory valuation, tangible and intangible long-term asset valuation, warranty and other obligations and commitments. Estimates are updated on an ongoing basis and are evaluated based on historical experience and current circumstances. Changes in facts and circumstances in the future may give rise to changes in these estimates which may cause actual results to differ from current estimates.
Fair Value Estimates
Pursuant to the Accounting Standards Codification (“ASC”) No. 820, “Disclosures About Fair Value of Financial Instruments”, the Company records its financial assets and liabilities at fair value. ASC No. 820 provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. ASC No. 820 establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
| Level 1 - | Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. | |
| Level 2 - | Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the asset/liability’s anticipated life. | |
| Level 3 - | Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. |
The carrying values for cash and cash equivalents, accounts receivable, investment in marketable securities, other current assets, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The carrying values of notes payable and other financing obligations approximate their fair values because interest rates on these obligations are based on prevailing market interest rates.
| 11 |
Concentrations
We currently rely on one manufacturer to supply us with our GPS SmartSole and one manufacturer to supply us with the GPS device included in the GPS SmartSole. The loss of either of these manufacturers could severely impede our ability to manufacture the GPS SmartSole.
As
of June 30, 2022, the Company had four customers representing approximately
As
of June 30, 2021, the Company had three customers representing approximately
The Company accounts for share-based awards to employees and nonemployees directors and consultants in accordance with the provisions of ASC 718, Compensation—Stock Compensation., and under the recently issued guidance following FASB’s pronouncement, ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under ASC 718, and applicable updates adopted, share-based awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service, or vesting, period. The Company values its equity awards using the Black-Scholes option pricing model, and accounts for forfeitures when they occur.
Marketable Securities
The
Company’s securities investments that are acquired and held principally for the purpose of selling them in the near term are classified
as trading securities. Trading securities are recorded at fair value based on quoted market price (level 1) on the balance sheet in current
assets, with the change in fair value during the period included in earnings. As of June 30, 2022 and December 31, 2021 the fair value
of our investment in marketable securities was $
Derivative Liabilities
Our derivative instrument liabilities are re-valued at the end of each reporting period, with changes in the fair value of the derivative liability recorded as charges or credits to income, in the period in which the changes occur. For bifurcated conversion options that are accounted for as derivative instrument liabilities, we determine the fair value of these instruments using the Black-Scholes option pricing model. This model requires assumptions related to the remaining term of the instrument and risk-free rates of return, our current Common Stock price and expected dividend yield, and the expected volatility of our Common Stock price over the life of the option.
At
June 30, 2022 and December 31, 2021, the balance of the derivative liabilities was $
Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted unless they are antidilutive. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive:
| June 30, | ||||||||
| 2022 | 2021 | |||||||
| Warrants | ||||||||
| Preferred B shares | ||||||||
| Preferred C shares | ||||||||
| Conversion shares upon conversion of notes | ||||||||
| Total | ||||||||
| 12 |
Segments
The
Company operates in
Recently Issued Accounting Pronouncements
In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As small business filer, the standard will be effective for us for interim and annual reporting periods beginning after December 15, 2022. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures.
Other recent accounting pronouncements issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.
3. INVESTMENT IN MARKETABLE SECURITIES
As
of December 31, 2020, the Company owned shares of Inventergy Global, Inc. common stock with a fair value of $
In
June 2019, the Company acquired shares of Inpixon’s restricted common stock (after giving effect to a
| 13 |
During
the period ended December 31, 2021, the Company sold of its Inpixon shares for total net proceeds of $
During
the six months ended June 30, 2022, the Company sold shares of its Inpixon shares for total proceeds of $
The
Company was able to obtain observable evidence that the remaining shares had a market value of $
4. INVENTORY
Inventories consist of the following:
| June 30, 2022 | December 31, 2021 | |||||||
| Raw materials | $ | $ | ||||||
| Finished goods | ||||||||
| Total Inventories | $ | $ | ||||||
5. PROPERTY AND EQUIPMENT
Property and equipment, net, consists of the following:
| June 30, 2022 | December 31, 2021 | |||||||
| Software | $ | $ | ||||||
| Website development | ||||||||
| Software development | ||||||||
| Equipment | ||||||||
| Less: accumulated depreciation | ( | ) | ( | ) | ||||
| Total property and equipment, net | $ | $ | ||||||
Depreciation
expense for the period ended June 30, 2022 and 2021 was $
6. NOTES & LOANS PAYABLE
The following table summarizes the components of our short-term borrowings:
| June 30, 2022 | December 31, 2021 | |||||||
| (a) Term loan | $ | $ | ||||||
| (b) Revolving line of credit | ||||||||
| (b) Revolving line of credit | ||||||||
| (c) CARE loans | ||||||||
| Total | $ | $ | ||||||
(a) Term loans
| 14 |
In
2022, the Company entered into an unsecured short-term loan agreement with a third party for an aggregate principal balance of $
In
September of 2019, the Company entered into an unsecured term loan agreement with a third party for an aggregate principal balance of
$
(b) Lines of Credit
The
Company obtained a revolving line of credit agreement with an accredited investor of $
The
line bears interest of
(c) CARE Loans
As
of December 31, 2021, the Company has assumed, due to lack of correspondence, until otherwise received, that twelve months of its EIDL
loan (see Note 8(b)), or $
7. CONVERTIBLE PROMISSORY NOTES – PAST DUE
As
of June 30, 2022 and December 31, 2021, the Company had a total of $
| June 30, 2022 | December 31, 2021 | |||||||
| Convertible Notes – with fixed conversion | $ | $ | ||||||
| Less: Debt discount | ||||||||
| Total convertible notes, net of debt discount | $ | $ | ||||||
| a) | Included
in Convertible Notes - with fixed conversion terms, are loans provided to the Company from various investors These notes carry simple
interest rates ranging from |
| 15 |
| At
December 31, 2020, balance of the convertible notes was $ During the six months ended June 30, 2022,
an additional $100,000 of the Company’s executive notes were transferred to third parties for cash. The transferred notes had no
change in terms thus |
8. CARE Loans
| June 30, 2022 | December 31, 2021 | |||||||
| a) PPP loan – short term | $ | $ | ||||||
| b) EIDL loan – short term | ||||||||
| b) EIDL loan – long term | ||||||||
| Total CARE loans | $ | $ | ||||||
(a) Paycheck Protection Program Loan
On
April 30, 2020, the Company executed a note (the “PPP Note”) for the benefit of MUFG Union Bank, NA (the “Lender”)
in the aggregate amount of $
During
the period ended June 30, 2022, the Company received notification that the loan was forgiven, and as such, $
| 16 |
(b) Economic Injury Disaster Loan
On June 10,
2020, the Company executed a secured loan with the U.S. Small Business Administration (SBA) under the Economic Injury Disaster Loan program
in the amount of $
As of
June 30, 2022, the Company calculated that 13 months of the 360 periods on the
9. RELATED PARTY TRANSACTIONS
Convertible Notes Due to Related Parties
During the
period ended December 31, 2021, the Company relieved the outstanding payables due to related parties by $
During 2020,
management elected to reduce the
On July 1,
2021, the annual interest on the notes was re-established to
Accrued wages
and costs - In order to preserve cash for other working capital needs, various officers, members of management, employees and directors
agreed to defer portions of their wages and sometimes various out-of-pocket expenses since 2011. As of June 30, 2022, and December 31,
2021, the Company owed $
10. DERIVATIVE LIABILITIES
Under authoritative guidance used by the FASB on determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, instruments which do not have fixed settlement provisions are deemed to be derivative instruments. The Company has issued certain convertible notes which conversion prices are based on a future market price. However, since the number of shares to be issued is not explicitly limited, the Company is unable to conclude that enough authorized and unissued shares are available to share settle the conversion option. As a result, the conversion option is classified as a liability and bifurcated from the debt host and accounted for as a derivative liability in accordance with ASC 815 and will be re-measured at the end of every reporting period with the change in value reported in the statement of operations.
At June 30,
2022 and December 31, 2021, the balance of the derivative liabilities was $
| 17 |
11. EQUITY
The Company has shares of preferred stock authorized, giving the Board of Directors of this corporation the authorization to (A) determine the number of series into which shares of Preferred Stock may be divided, (B) to determine the designations, powers, preferences, voting and other rights, and the qualifications, limitations and restrictions granted to or imposed upon the Preferred Stock or any series thereof or any holders thereof, (C) to determine and alter the designations, powers, preferences and rights, and the qualifications, limitations and restrictions granted to or imposed upon any wholly unissued series of Preferred Stock or the holders thereof, (D) to fix the number of shares of that series, and (E) to increase or decrease, within the limits stated in any resolutions of the Board of Directors originally fixing the number of the shares constituting any series (but not below the number of such shares then outstanding), the number the shares of any such series subsequent to the issuance of shares of that series.
From this pool the following preferred shares have been classified as:
Preferred Stock – Series A
During the year ended December 31, 2018, the Company authorized of Series A preferred shares, the Series A Preferred Stock shall, collectively, at all times have super-majority voting power equal to two-thirds (2/3rds) of the votes available to be cast on any matter subject to a shareholder vote. The subject preferred stock lacks any dividend rights, does not have liquidation preference, and is not convertible into common stock. During the year ended December 31, 2018, the Company issued million Series A preferred shares to certain officers and board members.
Effective January 31, 2020, Chris Walsh resigned from the Board of Directors and returned his Preferred A shares to Treasury, resulting in Preferred shares being outstanding currently.
At December 31, 2020 is was determined that the Preferred A shareholders having the majority vote, can agree to increase the number of authorized shares, if needed, to settle any convertible debt, and thus any derivative liabilities are not necessary to reserve for this.
Preferred Stock – Series B
During the
year ended December 31, 2019, the Company authorized shares of preferred stock to be designated available for Series B preferred
shares that have a value of $ each and are convertible into common shares at fixed price of $
During the
period ended December 31, 2020, the Company issued Series B preferred shares and warrants to an accredited investor for
their financings for an aggregate value of $
During the
period ended December 31, 2021, the two accredited investors converted Series B preferred shares into common shares at the
conversion price of $
Preferred Stock – Series C
During the
period ended December 31, 2020, the Company authorized shares of preferred stock to be designated available for Series C preferred
shares that have a stated value of $
During the
period ended December 31, 2020, the Company issued Series C preferred shares and warrants to two accredited investors for
their financings for an aggregate value of $
| 18 |
During the
period ended December 31, 2021, the Company issued Series C preferred shares and
During the
period ended December 31, 2021, the two accredited investors converted Series C preferred shares into common shares at
the conversion price of $
Common Stock
During the
period ending June 30, 2022, the Company issued shares of its common stock to various firms for services rendered, with a fair
value of $
During the
period ended June 30, 2022, the Company issued shares of common stock with a fair value of $
On October
15, 2021, the Company initiated a financing for gross proceeds of up to $
Common Stock Warrants
Since inception, the Company has issued numerous warrants to purchase shares of the Company’s common stock to shareholders, consultants and employees as compensation for services rendered.
A summary of the Company’s warrant activity and related information is provided below (the exercise price and the number of shares of common stock issuable upon the exercise of outstanding warrants have been adjusted to reflect a 1-for-75 reverse stock split.):
| Exercise Price $ |
Number of Warrants | |||||||
| Outstanding and exercisable at December 31, 2021 | – | |||||||
| Warrants exercised | ( |
) | ||||||
| Warrants granted | ||||||||
| Warrants expired | ||||||||
| Outstanding and exercisable at June 30, 2022 | - | |||||||
| Stock Warrants as of June 30, 2022 | ||||||||||||||
| Exercise | Warrants | Remaining | Warrants | |||||||||||
| Price | Outstanding | Life (Years) | Exercisable | |||||||||||
| $ | ||||||||||||||
| $ | ||||||||||||||
| $ | ||||||||||||||
During the
period ended June 30, 2022, the Company issued shares of common stock with a fair value of $
The outstanding and exercisable warrants at June 30, 2022 had an intrinsic value of approximately $.
| 19 |
Common Stock Options
Under the Company’s 2008 Equity Compensation Plan (the “2008 Plan”), we are authorized to grant stock options intended to qualify as Incentive Stock Options, “ISO”, under Section 422 of the Internal Revenue Code of 1986, as amended, non-qualified options, restricted and unrestricted stock awards and stock appreciation rights to purchase up to shares of common stock to our employees, officers, directors and consultants, with the exception that ISOs may only be granted to employees of the Company and its subsidiaries, as defined in the 2008 Plan.
The 2008 Plan provides for the issuance of a maximum of shares, of which, after adjusting for estimated pre-vesting forfeitures and expired options, approximately were available for issuance as of June 30, 2022.
options were granted during the period ending June 30, 2022.
12. COMMITMENTS & CONTINGENCIES
Bonuses
The Company
has an employment agreement with its CEO which, among other provisions, provide for the payment of a bonus, as determined by the Board
of Directors, in amounts ranging from
Contingencies
From time to time, we may be involved in routine legal proceedings, as well as demands, claims and threatened litigation that arise in the normal course of our business. The ultimate amount of liability, if any, for any claims of any type (either alone or in the aggregate) may materially and adversely affect our financial condition, results of operations and liquidity. In addition, the ultimate outcome of any litigation is uncertain. Any outcome, whether favorable or unfavorable, may materially and adversely affect us due to legal costs and expenses, diversion of management attention and other factors. We expense legal costs in the period incurred. We cannot assure you that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against us in the future, and these matters could relate to prior, current or future transactions or events. As of June 30, 2022, there was no pending or threatened litigation against the Company.
Covid-19
The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.
Due to COVID-19, we have experienced some changes in our business, that have been both positive and negative. Specifically, the Company’s IP licensing business has been negatively impacted by the global financial slowdown and many courts, judges and law firms are not working at full capacity, which is creating delays in finalizing licensing agreements or litigation. We have also experienced a small percentage of subscriptions being either cancelled or requested to be put on pause, due to financial hardships. On the positive side we saw an increase in product sales specifically with medical supplies and equipment. Overall, our revenues have not been materially impacted as a whole, however there have been some shifts with certain revenue streams doing better post COVID and others doing worse.
The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain.
13. SUBSEQUENT EVENTS
None.
| 20 |
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 2 of Part I of this report include forward-looking statements. These forward looking statements are based on our management’s current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “proposed,” “intended,” or “continue” or the negative of these terms or other comparable terminology. You should read statements that contain these words carefully, because they discuss our expectations about our future operating results or our future financial condition or state other “forward-looking” information. Many factors could cause our actual results to differ materially from those projected in these forward-looking statements, including but not limited to: variability of our revenues and financial performance; risks associated with product development and technological changes; the acceptance our products in the marketplace by existing and potential future customers; general economic conditions. You should be aware that the occurrence of any of the events described in this Quarterly Report could substantially harm our business, results of operations and financial condition, and that upon the occurrence of any of these events, the trading price of our securities could decline. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, growth rates, levels of activity, performance or achievements. We are under no duty to update any of the forward-looking statements after the date of this Quarterly Report to conform these statements to actual results.
Introduction
Unless otherwise noted, the terms “GTX Corp”, the “Company”, “we”, “us”, and “our” refer to the ongoing business operations of GTX Corp and our wholly-owned subsidiaries, Global Trek Xploration, and LOCiMOBILE, Inc.
Organization and Presentation
During the periods covered by the accompanying financial statements, GTX Corp and its subsidiaries were engaged in business operations that design, manufacture and sell various interrelated and complementary products and services in the wearable technology and Personal Location Services marketplace. GTX owns 100% of the issued and outstanding capital stock of its two subsidiaries - Global Trek Xploration, Inc. and LOCiMOBILE, Inc.
Global Trek Xploration is a California corporation which engages in the business of design, development, manufacturing, and sales of health and safety wearable technology solutions. Utilizing Global Positioning Satellite (“GPS”), Cellular, Radio Frequency (“RF”), Near Field Communications (“NFC”), WiFi, and Bluetooth low energy (“BLE”) as core technologies for monitoring and tracking assets. GTX is vertically integrated and provides hardware, software, and connectivity, delivering a complete end to end location-based platform that enables subscribers to track in real time the whereabouts of people, pets, or high valued assets. Our proprietary GPS devices, which consist of a miniature quad-band General Packet Radio Service (“GPRS”) transceiver, custom antenna, circuitry, battery, and inductive charging pad can be customized and integrated into numerous form factors. The finished products are then placed or worn so that their location and movement can be monitored in real time over the Internet through our 24x7 tracking portal or on a web-enabled cellular telephone.
| 21 |
Many of our core products and services are supported by an intellectual property portfolio of patents, patents pending, registered trademarks, copyrights, URLs and a library of software source code, all of which is also managed by Global Trek.
LOCiMOBILE, Inc., is the Company’s digital platform which has been at the forefront of Smartphone application (“App”) development since 2008. With a suite of mobile applications that turn the iPhone, iPad, Android and other GPS enabled handsets into a tracking device which can be tracked from handset to handset or through our tracking portal or on any connected device with internet access. LOCiMOBILE has launched over 20 Apps across multi mobile device operating systems and continues to launch consumer and enterprise apps.
Operations
The Company designs, develops, manufactures, sells, and distributes health and safety products and services, and other related medical supplies and equipment, through a global business to business (“B2B”) network of resellers, affiliates, distributors, nonprofit organizations, local, state, and federal government agencies, police departments, manufacturers reps and retailers, and direct business to consumer (“B2C”). Offering a variety of electronic and non-electronic devices and equipment, a proprietary Internet of things (“IoT”) enterprise monitoring platform and a licensing subscription business model. The Company provides a complete end to end solution of hardware, middleware, apps, connectivity, licensing, and professional services, letting our customers know where or how someone, or something, is at the touch of a button, delivering safety, security, and peace of mind in real-time. Except for our military products and medical protective equipment, all of our consumer and enterprise tracking products funnel into the GTX Corp IoT monitoring platform which supports end user customers in over 35 countries. The Company is also in the business of licensing intellectual property and monetizing its patent portfolio.
Overview
During the second quarter of 2022, we focused on ramping up production for our GPS SmartSoles, getting all of our international distributors back online and fulfilling their backorders, finishing our new NFC product which we expect to launch in Q3 2022, continued to support the Endstate NFC/NFT rollout, and attended the LD Micro conference to meet with investors and discuss our REG A, which is priced above market at $.03.
Revenues were not as anticipated for the second quarter 2022, mostly due to a significant spike in COVID cases, ongoing supply chain disruptions, looming worries about the overall health of the economy, and general market volatilities, hence we did not meet our revenue expectations and revenues were down by 40% compared to the comparable previous quarter. Under these challenging circumstances, we did however see continued demand for our SmartSoles, with orders to fulfill throughout the rest of the year. More domestic product sales will subsequently increase our higher margin subscription business which saw a 12% increase over the comparable previous quarter. Also, our Endstate NFC/NFT business increased, with now close to 2,400 units on order for delivery in Q3, 2022. And on the cash flow and balance sheet side, we continued to keep a low burn rate and reduced our net losses by 23% from the comparable previous quarter, took on no new convertible debt, management continued to defer and accrue 34% of our salary and we raised from our Reg A, $150,000.00 during the second quarter 2022, and subsequently raised an additional $30,000.00 in July.
| 22 |
With the recent spike in COVID cases across the country we did continue to see demand for protective medical supplies and fulfill orders daily. With the continued demand for our SmartSoles we increased our production commitment for an additional 1,000 units. And we released a new version of our tracking app along with a new ecommerce store on the Shopify platform, which enables us to have more capabilities to sell through social media platforms such as Facebook and Instagram, along with having better accounting and inventory management capabilities as we start ramping up domestic sales. We also implemented Wi-Fi capabilities on the SmartSole platform which will enable us to track indoors and gets us one step closer to implementing the Bluetooth feature which will then convert the SmartSole from a tracking device to a mobile hub capable of interacting with other wearable medical devices.
We remain optimistic that COVID-19 pandemic is behind us. However, we still have some inventory on hand and solid relationships with our vendors so as long as there is demand we will be ready to serve our customers. Our focus continues to be on ramping up sales of the new SmartSoles, NFC products, other medical wearable devices, A.I. and IP licensing. Health & Safety, Track & Trace. Everyone wants to be healthy, live better and longer, and know where someone or something is and has been. We believe we are in a position to monetize from these trends and keep hearing from many of our B2B customers and international distributors that they want more wearable solutions and technology to serve the medical community.
Results of Operations
The following discussion should be read in conjunction with our interim consolidated financial statements and the related notes that appear elsewhere in this Quarterly Report.
Three Months Ended June 30, 2022 (“Q2 2022”) Compared to the Three Months Ended June 30, 2021 (“Q2 2021”)
| Three Months Ended June 30, | ||||||||||||||||
| 2022 | 2021 | |||||||||||||||
| $ | % of Revenues | $ | % of Revenues | |||||||||||||
| Product sales | 31,245 | 49 | % | 112,656 | 71 | % | ||||||||||
| Service income | 33,156 | 51 | % | 46,947 | 29 | % | ||||||||||
| IP royalties | - | 0 | % | - | 0 | % | ||||||||||
| Total revenues | 64,401 | 100 | % | 159,603 | 100 | % | ||||||||||
| Cost of products sold | 35,989 | 56 | % | 29,959 | 19 | % | ||||||||||
| Cost of service revenue | 5,973 | 9 | % | 18,360 | 12 | % | ||||||||||
| Cost of licensing revenue | - | 0 | % | - | 0 | % | ||||||||||
| Cost of goods sold | 41,962 | 65 | % | 48,319 | 30 | % | ||||||||||
| Gross profit | 22,440 | 35 | % | 111,284 | 70 | % | ||||||||||
| Operating expenses: | ||||||||||||||||
| Wages and benefits | 131,323 | 204 | % | 120,160 | 75 | % | ||||||||||
| Professional fees | 77,177 | 120 | % | 97,790 | 61 | % | ||||||||||
| Sales and marketing expenses | 5,058 | 8 | % | 59,802 | 37 | % | ||||||||||
| General and administrative | 27,292 | 42 | % | 41,650 | 26 | % | ||||||||||
| Total operating expenses | 240,850 | 374 | % | 319,402 | 200 | % | ||||||||||
| Gain/(loss) from operations | (218,410 | ) | -339 | % | (208,118 | ) | -130 | % | ||||||||
| Other (expense)/income, net | (7,813 | ) | -12 | % | (47,370 | ) | -30 | % | ||||||||
| Net income/(loss) | (226,223 | ) | -351 | % | (255,488 | ) | -160 | % | ||||||||
| 23 |
Revenues
Revenues were $64,401 for the Q2 2022 as compared to $159,603 for the Q2 2021, representing a decrease of 60%, This decrease was primarily driven from transitioning out of direct-to-consumer PPE sales during Covid into our core B2B business.
During Q2 2022, the Company’s customer base and revenue streams were comprised of approximately 88.21% B2B (Wholesale Distributors and Enterprise Institutions), 11.79% B2C (consumers and government agencies who bought on the behalf of consumers, through our online ecommerce platform and through Amazon, Google and iTunes), 0% IP (our monetization campaign from consulting, licensing and asserting our patents) and 0% Military and Law Enforcement.
During Q2 2021, the Company’s customer base and revenue streams were comprised of approximately 22.47% B2B (Wholesale Distributors and Enterprise Institutions), 77.05% B2C (consumers and government agencies who bought on the behalf of consumers, through our online ecommerce platform and through Amazon, Google and iTunes), 0% IP (our monetization campaign from consulting, licensing and asserting our patents) and 0.48% Military and Law Enforcement.
Cost of goods sold
Cost of goods sold were $41,962 for the Q2 2022 compared to $48,319 for the Q2 2021, representing a decrease of 13%. This decrease was primarily due to the shift from COVID related PPE’s with less margins, to the higher margin 4G SmartSoles and the increase in recurring fees.
We expect our margins to increase in 2022 once we start ramping up our subscriptions and licensing and sell more of our proprietary products like our SmartSoles, where we have no competition. Our overall gross margin was slightly lower in 2021, predominately because most of our revenues came from product sales which require competitive pricing, and that includes shipping charges. In order to be competitive with the major online retailers (many of them include free shipping) we had to reduce our shipping charges to be in line with competitors.
Wages and benefits
Wages and benefits increased $11,163, or 9%, in Q2 2022 as compared to Q2 2021. This increase was primarily the result of one of our executive sales staff taking on more duties as we transition back into our core GPS and SmartSole business.
Professional fees
Professional fees consist of costs attributable to consultants and contractors who primarily spend their time on legal, accounting, product development, business development, corporate advisory services and shareholder communications. Such costs decreased $20,611 or 21% in Q2 2022 as compared to in Q2 2021. Even though some professional fees have decreased as more responsibilities were transferred from outside contractors and consultants to in-house personnel. Those fees related to investor relations and business development have increased due to new products lines and the impending release of the company’s updated SmartSole products.
| 24 |
Sales and marketing expenses
Sales and marketing expenses decreased by 92% or $54,744 in Q2 2022 in comparison to Q2 2021. This decrease was primarily due to a large Company awareness campaign in 2021 compared to 2022.
General and administrative
General and administrative costs in Q2 2022 decreased by $14,358 or 34% in comparison to Q2 2021, mostly due to adjustments to prior period accruals.
Other income/(expense), net
Other expense, net decreased 84% or $39,556 in Q2 2022 compared to Q2 2021. This decrease was primarily as a result of decrease in the amortization of debt discounts and $34,191 in recovery of EDD payments during Covid.
Net income/(loss)
Net loss decreased by 11% or $29,260 from Q2 2022 to Q2 2021 primarily as a result of the decrease in the amortization of debt discounts and $34,191 in recovery of EDD payments during Covid.
Six Months Ended June 30, 2022 (“Q1 and Q2 2022”) Compared to the Six Months Ended June 30, 2021 (“Q1 and Q2 2021”)
| Six Months Ended June 30, | ||||||||||||||||
| 2022 | 2021 | |||||||||||||||
| $ | % of Revenues | $ | % of Revenues | |||||||||||||
| Product sales | 163,925 | 70 | % | 284,989 | 73 | % | ||||||||||
| Service income | 68,992 | 30 | % | 105,135 | 27 | % | ||||||||||
| IP royalties | - | 0 | % | - | 0 | % | ||||||||||
| Total revenues | 232,917 | 100 | % | 390,124 | 100 | % | ||||||||||
| Cost of products sold | 123,934 | 53 | % | 142,054 | 36 | % | ||||||||||
| Cost of service revenue | 12,891 | 6 | % | 53,427 | 14 | % | ||||||||||
| Cost of licensing revenue | - | 0 | % | - | 0 | % | ||||||||||
| Cost of goods sold | 136,824 | 59 | % | 195,481 | 50 | % | ||||||||||
| Gross profit | 96,092 | 41 | % | 194,643 | 50 | % | ||||||||||
| Operating expenses: | ||||||||||||||||
| Wages and benefits | 246,962 | 110 | % | 246,962 | 63 | % | ||||||||||
| Professional fees | 197,960 | 75 | % | 197,960 | 51 | % | ||||||||||
| Sales and marketing expenses | 69,738 | 7 | % | 69,738 | 18 | % | ||||||||||
| General and administrative | 88,399 | 38 | % | 89,701 | 23 | % | ||||||||||
| Total operating expenses | 534,425 | 229 | % | 604,361 | 155 | % | ||||||||||
| Gain/(loss) from operations | (438,333 | ) | -188 | % | (409,718 | ) | -105 | % | ||||||||
| Other (expense)/income, net | 17,725 | 8 | % | (136,197 | ) | -35 | % | |||||||||
| Net income/(loss) | (420,608 | ) | -181 | % | (545,915 | ) | -140 | % | ||||||||
| 25 |
Revenues
Revenues as a whole in Q1 and Q2 2022 decreased by 40% or $157,207 in comparison to Q1 and Q2 2021, a result of the reduction in demand for PPP’s and the inability to ship any SmartSoles during the 1st quarter due to supply chain delays. We continue to fulfill pre-sale orders daily and expect SmartSole production to catch up with orders over the next few quarters. Additionally, we are seeing an uptick in PPE demand and increased sales as a result of the new COVID spike.
Cost of goods sold
Cost of goods sold increased by 30% or $58,658 during Q1 and Q2 2022 in comparison to Q1 and Q2 2021 primarily due to the shift from purchases of low margin health and safety inventories to the higher margin SmartSoles.
Wages and benefits
Wages and benefits during Q1 and Q2 2022 increased by 3% or $8,126 in comparison to Q1 and Q2 2021, primarily due to employee benefits and conferences.
Professional fees
Professional fees consist of costs attributable to consultants and contractors who primarily spend their time on legal, accounting, product development, business development, corporate advisory services and investor relations. Such costs decreased $22,621 or 11% during Q1 and Q2 2022 as compared to Q1 and Q2 2021, primarily due to the Company’s decreased need for outside consultants.
Sales and marketing expenses
Sales and marketing expenses decreased by 78% or $54,150 during Q1 and Q2 2022 in comparison to Q1 and Q2 2021. Primarily due to costs related to the ramp up of increased health and safety products and the associated advertising in 2021.
General and administrative
General and administrative costs during Q1 and Q2 2022 decreased by $1,300 or 1% in comparison to Q1 and Q2 2021, thus remaining constant with reductions in insurance fees and corporate expenses being offset with increased product development and general occupancy costs.
Other income/(expense), net
Other expense, net decreased 113% or $153,922 from Q1 and Q2 2022 to Q1 and Q2 2021 primarily as a result of a $67,870 from the forgiveness of a CARE loan, the decrease in the amortization of debt discounts and $34,191 in recovery of EDD payments during Covid. These gains offset the increase in interest expense and financing cots related to debt and the Reg A.
Net income/(loss)
Net loss decreased by 22% or $118,284 from Q1 and Q2 2022 to Q1 and Q2 2021 primarily as a result of $67,870 from the forgiveness of a CARE loan, the decrease in the amortization of debt discounts and $34,191 in recovery of EDD payments during Covid, all while operating expenses remaining fairly stable during the transition from health and safety products back to our core GPS and SmartSole business.
| 26 |
Liquidity and Capital Resources
As of June 30, 2022, we had $61,135 of cash and cash equivalents, and a working capital deficit of $2,983,441, compared to $138,342 of cash and cash equivalents and a working capital deficit of $2,829,165 as of December 31, 2021.
During the six months ended June 30, 2022, our net loss was $420,608 compared to a net loss of $545,915 for the six months ended June 30, 2021. Net cash used in operating activities in the six months ended June 30, 2022 and in the six months ended June 30, 2021 was $269,697 and $243,364, respectively.
Net cash used in investing activities during the six months ended June 30, 2022 was $0, as compared to net cash used in investing activities during the six months ended June 30, 2021 which was $63,242 which consisted of proceeds totaling $1,258 received from the sale of marketable securities and $64,500 in developments cost assets.
Net cash provided by financing activities during the six months ended June 30, 2022 was $192,490 and consisted of $150,000 received form the purchase of 5,000,000 shares of common stock at $0.03 per share, $25,000 received for the conversion of warrants, $25,000 from the issuance of debt and $34,180 from draws upon our line of credit. This was offset by payments on debt of $32,510 and $9,180 on the line of credit. Net cash used by financing activities during the six months ended June 30, 2021 was $658,707 and consisted of $16,293 in upon our lines of credit and a term loan, and $675,000 received from financings. This represents a decrease of 88%. This reduction in additional financings is directly related to the Company not relying on convertible notes for financings, with no new convertible notes being issued.
Because revenues from our operations have, to date, been insufficient to fund our working capital needs, we currently rely on the cash we receive from our financing activities to fund our growth, capital expenditures and to support our working capital requirements. The sale of our products and services is expected to enhance our liquidity in 2022, although the amount of revenues we receive in 2022 still cannot be estimated.
Until such time as our products and services can support our working capital requirement, we expect to continue to generate revenues from our other licenses, subscriptions, international distributors, hardware sales, professional services and new customers in the pipeline. However, the amount of such revenues is unknown and is not expected to be sufficient to fund our working capital needs. For our internal budgeting purposes, we have assumed that such revenues will not be sufficient to fund all of our planned operating and other expenditures during 2022. In addition, our actual cash expenditures may exceed our planned expenditures, particularly if we invest in the development of improved versions of our existing products and technologies, and if we increase our marketing expenses. Accordingly, we anticipate that we will have to continue to raise additional capital in order to fund our operations in 2022 No assurance can be given that we will be able to obtain the additional funding we need to continue our operations.
In order to continue funding our growth, IP and working capital needs and new product development costs, during the second quarter of 2022 we continued to draw down on our credit line to fund purchase orders. However, no assurance can be given that the investor will provide the funding, if and when requested by us.
Going Concern
The consolidated financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has stockholders’ deficit of $3,052,303 and negative working capital of $2,983,441 as of June 30, 2022 and used cash in operations of $269,697 during the current period then ended. A significant part of our negative working capital position at June 30, 2022 consisted of $923,130, of amounts due to various accredited investors of the Company for convertible promissory notes, loans and a letter of credit. The Company anticipates further losses in the development of its business. Please see the section entitled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2021 for more information regarding risks associated with our business.
| 27 |
Off-Balance Sheet Arrangements
There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
Inflation
We do not believe our business and operations have been materially affected by inflation.
Critical Accounting Policies and Estimates
There are no material changes to the critical accounting policies and estimates described in the section entitled “Critical Accounting Policies and Estimates” under Item 7 in our Annual Report on Form 10-K for the year ended December 31, 2021.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a “smaller reporting company”, we are not required to provide the information under this Item 3.
ITEM 4. CONTROLS AND PROCEDURES.
Evaluation of Disclosure Controls and Procedures
Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e)) under the Exchange Act) that is designed to ensure that information required to be disclosed by the Company in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our management, including our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.
Based on the evaluation as of June 30, 2022, for the reasons set forth below, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
None.
ITEM 1A. RISK FACTORS.
These are not all of the risks associated with the Company and must be used in conjunction with those disclosed in the most recent December 31, 2021 10K filing.
| 28 |
The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company’s business is highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a local and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain.
Due to COVID-19, we have experienced some changes in our business, that have been both positive and negative. Specifically, the Company’s IP licensing business has been negatively impacted by the global financial slowdown and many courts, judges and law firms are not working at full capacity, which is creating delays in finalizing licensing agreements or litigation. We have also experienced a small percentage of subscriptions being either cancelled or requested to be put on pause, due to financial hardships. On the positive side we saw an increase in product sales specifically with medical supplies and equipment. Overall, our revenues have not been materially impacted as a whole, however there have been some shifts with certain revenue streams doing better post COVID and others doing worse.
The severity of the impact of the COVID-19 pandemic on the Company’s business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s customers, service providers and suppliers, all of which are uncertain and cannot be predicted. As of the date of issuance of Company’s financial statements, the extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain.
ITEM 2.(a). UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
On January 14, 2022, we issued 4,000,000 in common stock, valued at $39,600 to a firm as part of their agreement.
On January 21, 2022, an investor converted 10,000,000 of warrants into 10,000,000 shares of common stock at a strike of $0.0025 for $25,000 in cash.
On April 1, 2022, we issued 1,200,000 in common stock, valued at $11,400 to a firm as part of their agreement.
On April 6, 2022, an investor invested $150,000 in the Company’s Reg A and received 5,000,000 of shares of common stock at a price of $0.03.
On April 12, 2021, we issued 1,904,762 in restricted common stock to a firm as part of their agreement with a value of $18,476 on the date of the agreement.
On April 1, 2022, we issued 1,200,000 in common stock, valued at $11,400 to a firm as part of their agreement.
On May 12, 2022, we issued 500,000 in common stock, valued at $3,450 to a firm as part of their agreement.
The issuance of the above shares was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
ITEM 5. OTHER INFORMATION.
None.
| 29 |
ITEM 6. EXHIBITS.
(a) Exhibits
| 31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act | |
| 31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act | |
| 32.1 | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act | |
| 32.2 | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act | |
| 101.INS | Inline XBRL Instance Document | |
| 101.SCH | Inline XBRL Taxonomy Extension Schema | |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation | |
| 101.DEF | Inline XBRL Taxonomy Extension Definition | |
| 101.LAB | Inline XBRL Taxonomy Extension Label | |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 30 |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GTX CORP | ||
| Date: August 12, 2022 | By: | /s/ ALEX MCKEAN |
| Alex McKean, | ||
| Chief Financial Officer (Principal Financial Officer) | ||
| Date: August 12, 2022 | By: | /s/ PATRICK BERTAGNA |
| Patrick Bertagna, | ||
| Chief Executive Officer |
| 31 |